Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Galapagos ( (GLPG) ) has shared an update.
On March 31, 2026, Galapagos announced a binding framework agreement with Gilead Sciences tied to Gilead’s planned $1.675 billion acquisition of US biotech Ouro Medicines, securing shared rights to Ouro’s T cell engager portfolio for autoimmune diseases. The deal centers on gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager with Fast Track and Orphan Drug designations in the U.S. for autoimmune hemolytic anemia and immune thrombocytopenia and promising early Phase 1/2 data, with registrational studies expected to start as early as 2027.
Under the agreement, Galapagos will fund 50% of the Ouro acquisition consideration and milestone payments and will co-fund development of gamgertamig, bearing all pre-registrational costs and sharing registration-enabling expenses equally with Gilead. Gilead will take global commercialization responsibility outside KeyMed’s territories, paying Galapagos tiered royalties of 20–23% on net sales and potential milestones, while Galapagos also gains three additional preclinical autoimmune programs on which Gilead may later opt into 50/50 profit splits.
A key feature is an amendment to Galapagos and Gilead’s prior collaboration, allowing Galapagos to deploy at least $500 million of its cash independently of Gilead, including up to $150 million for possible share buybacks or other capital returns, which enhances strategic flexibility and capital allocation options. The transaction, treated as a related-party deal given Gilead’s 25.35% stake in Galapagos, was reviewed under Belgian corporate law, with an independent board committee and the statutory auditor both concluding that the terms are not manifestly disadvantageous to Galapagos and are justified by the expected benefits.
The most recent analyst rating on (GLPG) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
Spark’s Take on GLPG Stock
According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.
GLPG scores strongest on financial positioning (very low leverage and large cash resources) and supported valuation (low P/E). The main offset is persistent negative operating/free cash flow and earnings quality concerns highlighted by non-recurring profit drivers and ongoing restructuring/wind-down cash needs; technical signals are broadly neutral.
To see Spark’s full report on GLPG stock, click here.
More about Galapagos
Galapagos NV is a Belgium-based biopharmaceutical company listed on Euronext and Nasdaq, focused on developing innovative therapies, particularly in immunology and autoimmune diseases. The company partners with large pharmaceutical groups such as Gilead Sciences to co-develop and commercialize advanced biologics and cell-engager programs targeting severe, immune-mediated conditions.
Average Trading Volume: 133,932
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.92B
For detailed information about GLPG stock, go to TipRanks’ Stock Analysis page.